BerGenBio meets first efficacy endpoint in phase II trial with selective AXL inhibitor BGB324 (bemcentinib) in NSCLC
Trial aims to evaluate the effectiveness of BGB324 (bemcentinib) in preventing and reversing resistance to targeted therapyBergen, Norway, January 9, 2018 – BerGenBio ASA (OSE:BGBIO) , a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors as a potential cornerstone of combination cancer therapy, announces that the first efficacy endpoint has been met in its phase II clinical trial evaluating BGB324 (bemcentinib), a selective AXL inhibitor, in combination with erlotinib in patients with advanced non-small cell lung cancer (